In contrast, DLBCL ABC exhibit chronic BCR activation (e.g. through CD79A/B mutations) and present with other genetic alterations such as BCL2 amplifications or INK4-ARF deletions. This evidence concerns the gene CDKN2A and diffuse large B-cell lymphoma.